VTN and COVID-19: In human patients, prior history of complement activation and coagulation disorders predict the severity of COVID-19 (Ramlall et al. 2020; Afzali et al. 2022), such that low baseline blood clotting and higher baseline complement proteins could also predispose North American bats to infection with SARS-CoV-2.